Q1 Earnings Forecast for Kamada Issued By HC Wainwright

Kamada Ltd. (NASDAQ:KMDA) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Kamada in a research note issued to investors on Thursday, January 8th. HC Wainwright analyst A. Fein forecasts that the biotechnology company will earn $0.10 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.11 EPS, FY2029 earnings at $0.77 EPS and FY2030 earnings at $0.82 EPS.

KMDA has been the subject of several other research reports. Benchmark reissued a “buy” rating on shares of Kamada in a report on Thursday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.00.

Kamada Trading Up 1.1%

Shares of NASDAQ KMDA opened at $7.95 on Friday. The company has a 50 day simple moving average of $7.01 and a two-hundred day simple moving average of $7.14. The stock has a market cap of $457.20 million, a price-to-earnings ratio of 22.08, a PEG ratio of 0.68 and a beta of 0.93. Kamada has a 12 month low of $5.54 and a 12 month high of $9.15.

Kamada (NASDAQ:KMDA) last issued its earnings results on Monday, November 10th. The biotechnology company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The firm had revenue of $47.01 million during the quarter, compared to analysts’ expectations of $154.21 million.

Institutional Investors Weigh In On Kamada

Several hedge funds have recently modified their holdings of the company. ARK Investment Management LLC acquired a new stake in Kamada in the second quarter valued at approximately $1,972,000. Goldman Sachs Group Inc. purchased a new position in shares of Kamada during the 1st quarter valued at approximately $497,000. Huntleigh Advisors Inc. lifted its position in shares of Kamada by 3.9% during the 2nd quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock valued at $1,052,000 after buying an additional 5,151 shares in the last quarter. Acadian Asset Management LLC grew its stake in Kamada by 3.1% in the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock valued at $2,053,000 after acquiring an additional 7,925 shares during the period. Finally, Trexquant Investment LP purchased a new stake in Kamada in the 1st quarter worth $82,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.